IRON Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -4.59%, SMA50 -10.87%, SMA200 -1.0%). The stock’s 14-day RSI is 45.34 (neutral), while the ATR of 5.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.75% below its high and over 120.34% above its low. Average 10-day trading volume of 520.39 thousand shares is in line with the 3-month average of 528.87 thousand, indicating normal recent market interest.

Disc Medicine, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.53. This means the shares are trading above this model’s fair value.

Disc Medicine, Inc. (NASDAQ:IRON) closed at $76.84 USD, losing -$2.39 (-3.02%) from the previous close of $79.23. The stock is currently mid-range between its 52-week high and low $40.00 and $99.50. With a market capitalization of about $2.95 billion, Disc Medicine, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.05). Key stats such as the average daily volume over the past year has been around 527.22 thousand shares, in line with its 52-week average. Headquartered in Watertown, MA, Disc Medicine, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John D. Quisel, the company employs approximately 165 people and listed since August 12, 2020. Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company.

Disc Medicine, Inc. generated EPS of -$5.36 over the past year. Five-year average earnings growth is 38.12%. Wall Street analysts project EPS growth of -21.26% annually over the next five years. The latest quarter delivered EPS of -$1.54. The next quarter is forecast at -$1.71. Next year's EPS is expected at -$28.82. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $153.00 to $79.00. The high target offers 99.12% upside. The low target suggests 2.81% downside. The mean target is $111.59. This offers 45.22% upside. Disc Medicine, Inc. earnings surprise history is a mixed track record. The quarter that ended July 30, 2026, missed forecasts by -9.94%. The prior quarter beat by 1.68%. Over the last six quarters, Apple has recorded several small beats. These include 3.03% in May 07, 2025.

Disc Medicine, Inc. has 38.20 million shares outstanding. The public float is 32.75 million shares, elevated short interest at 22.27% of float. This equals 7.29 million shares. The short ratio is 8.8 days. Institutional investors hold 122.53% of the float. Insiders own 7.78%. AI DMI LLC holds 2.81 million shares, Quisel John D has 226.06 thousand shares and Atlas Venture Fund X, L.P. has 198.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 62.86 thousand shares across 19 transactions.

Disc Medicine, Inc. trades at a P/E ratio of -11.85, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.7 trading at moderately above to book value. The P/FCF stands at -15.19, also below market averages.

Disc Medicine, Inc. (NASDAQ:IRON) shares are flat -6.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Disc Medicine, Inc. trading at a premium to the broader market with a P/E of -11.85. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $84.02, suggesting 9.34% upside. Our AI forecast model points to short-term weakness (-0.6% over two weeks), a medium-term rise (41.23% over three months), and a longer-term gain (10.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Disc Medicine, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.6%, with price expected at $76.38 by September 18, 2026, within a range of $74.93 to $77.79 3-Month Outlook: Projected rise of 41.23%, reaching $108.52 by December 03, 2026, with a range of $102.19 to $114.20. 1-Year Outlook: Projected gain of 10.67%, with price at $85.04 by September 03, 2027, within a range of $80.38 to $88.79.